Greg Smith

It is a pleasure to serve under your chairmanship, Mrs Barker. I was reflecting with my constituents Greg and Sally, whose son has a brain tumour, when I met them in my constituency office this morning—they also attended the all-party parliamentary group meeting a few weeks ago—on what has actually changed since I last spoke in a Backbench Business debate on brain tumours in 2023, and the sorry answer on funding is not a lot, and certainly not enough. In the few moments I have in the debate this afternoon, I want to cut to the chase and ask the Minister some direct questions about how we get that money spent and how we get real results to find cures and ways to prolong lives. To start on that, we must have a clear breakdown of the total spend on brain cancers by year over the last decade and how that breaks down by actual treatments; research into treatments, including into how much has been spent on trials; research into other areas with a bearing on brain cancer outcomes; research into how each of those involves artificial intelligence; and infrastructure. Specifically, I would very much like the Minister to address the issue of how the Government are planning to make the radical change in approach to brain tumour detection and treatment that is necessary for the UK to achieve its ambition to move from the fourth to the first quartile for survival in nine years. That is a worthy ambition, but we need to see the detail and the concrete steps that will be taken. It will involve answering big questions about artificial intelligence and other innovations. What I will say in my last few seconds is, given that brain cancer is the biggest killer of under-40s, we need to challenge the idea that it is really a rare cancer and ask whether the definition of “rare” is fit for purpose in the modern age.